CD274 and cancer: In the checkmate-358 study, 24 patients with recurrent/metastatic HPV-associated cervical (n = 19) and vulvar/vaginal (n = 5) cancer were treated with the checkpoint inhibitor nivolumab; the overall response rate was 20% and the disease control rate was 80%, regardless of the PD-L1 status [51].